Docetaxel, Carboplatin and Concomitant Radiotherapy for Unresectable Squamous Cell Carcinoma of the Head and Neck: Pharmacokinetic and Clinical Data of a Phase I-II Study

Mario Airoldi, Luigi Cattel, Giorgio Cortesina, Carlo Giordano, Fulvia Pedani, Valeria Recalenda, Marco Danova, Anna Maria Gabriele, Valeria Tagini, Camillo Porta, Cesare Bumma

Research output: Contribution to journalArticle

Abstract

Concomitant chemoradiotherapy is the most effective treatment of unresectable head and neck cancer. Docetaxel and carboplatin are two active drugs that potentiate radiotherapy. Thirty patients (median age = 56 years; median Eastern Cooperative Oncology Group performance status = 1) received radiotherapy (70 Gy, 2 Gy/d, 5 d/wk) concurrent with carboplatin AUC 0.3 to 0.5 on day 1-5, weeks 1, 3, 5, 7, and docetaxel 15 to 25 mg/m2 on day 4 of weeks 2, 4, and 6. Site of unresectable squamous cell carcinoma was as follows: oropharynx, 41%; hypopharynx, 27%; oral cavity, 16%; and larynx, 16%. Stage was III in 13% and IV in 87%. In 11 patients, pharmacokinetic parameters were evaluated. Acute G4 toxicity was as follows: neutropenia, 20%; mucositis, 33%. We had the following acute G3 toxicities: mucositis, 40%; neutropenia, 37%; dermatitis, 23%; and anemia, 13%. The maximum tolerated dosage was area under the curve 0.5 for carboplatin and 20 mg/m2 for docetaxel. Median radiotherapy dose was 69 Gy, and 175 out of 210 courses (83%) were administered. At the end of the treatment, we had 20 complete responses (CR) (67%), 9 partial responses (30%), and 1 no change (3%). After radial neck dissection, 2 patients achieved a CR (overall CR = 73%). After a median follow-up of 2.5 years, we had a 3-year local progression-free survival of 85%, failure-free survival of 69%, and overall survival of 60%. A significant increase of Cmax of carboplatin concentration was noted at the beginning of weeks 3, 5, and 7. Total plasma platinum raises during each course of 5 days of carboplatin without reaching a steady state. Carboplatin, docetaxel, and concomitant conventional radiotherapy is a feasible and effective treatment of unresectable head and neck cancer. The concurrent administration of two drugs does not alter pharmacokinetic drug behavior compared with single-agent data.

Original languageEnglish
Pages (from-to)155-163
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume27
Issue number2
DOIs
Publication statusPublished - Apr 2004

    Fingerprint

Keywords

  • Carboplatin
  • Docetaxel
  • Head and neck cancer
  • Pharmacokinetic
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this